Veliparib (ABT-888)

Catalog No.S1004 Synonyms: NSC 737664

Veliparib (ABT-888) Chemical Structure

Molecular Weight(MW): 244.29

Veliparib (ABT-888) is a potent inhibitor of PARP1 and PARP2 with Ki of 5.2 nM and 2.9 nM in cell-free assays, respectively. It is inactive to SIRT2. Phase 3.

Size Price Stock Quantity  
In DMSO USD 156 In stock
USD 120 In stock
USD 370 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Cited by 40 Publications

9 Customer Reviews

  • (A) OVCAR-8 cells were exposed to the indicated concentrations of FdUrd along with vehicle, 3 μM ABT-888 or 300 nM AZD2281 for 24 h. Following washing, ABT-888 and AZD2281 were re-added to the plates initially exposed to these agents, and cells were cultured in the continued presence of ABT-888 and AZD2281 for 8 d until colonies formed. (B) OVCAR-8 cells were exposed continuously to the indicated agents for 8 d. (C) OVCAR-8 cells treated as in (A) except that the indicated concentrations of ABT-888 were used.

    Cancer Research, 2011, 71: 4944-4954. Veliparib (ABT-888) purchased from Selleck.

    OVCAR-8 cells were plated, treated with indicated concentrations of FdUrd and 3 μM ABT-888 using the exposure schemes depicted in (C) and assayed for clonogenicity (D).

    Cancer Research, 2011, 71: 4944-4954. Veliparib (ABT-888) purchased from Selleck.

  •  

    Number of foci detected using laser confocal microscopy and fluorescent Fluor 647 anti-H2A.X-phosphorylated (Ser139) antibody. Double-stranded breaks (red) are clearly augmented in cells incubated with 500 nmol/l of ABT-888 and 500 nmol/l of AZD-2281 compared with PBS and 1% dimethyl sulfoxide controls. Image analysis was performed using ImageJ and the ‘analyze particle’ function.

    Nucl Med Commun 2011 32, 1046-1051. Veliparib (ABT-888) purchased from Selleck.

    Logarithmic growth curves of human Burkitt lymphoma cells over 5 days with 500 nmol/l of ABT-888 and AZD-2281 in combination with 0 Gy (a), 4 Gy (b), 8 Gy (c), and 12 Gy (d) of external beam radiation. The maximal relative reduction was 65.5% of viable cells and occurred with AZD-2281 (500 nmol/l) on day 5. DMSO, dimethyl sulfoxide.

    Nucl Med Commun 2011 32(11), 1046-51. Veliparib (ABT-888) purchased from Selleck.

  • Colorimetric poly(ADP-ribose) polymerase (PARP) activity assay showing the relative activity of the PARP-1 enzyme in Raji lymphocyte tumor cells. Results show a highly significant difference in PARP activity in the controls [PBS and dimethyl sulfoxide (DMSO)] compared with 24 h incubation with 500 nmol/l of ABT-888 and 500 nmol/l of AZD-2281. A significant increase in PARP enzyme activity is shown in DMSO-incubated cells compared with PBS control.* P < 0.05.

    Nucl Med Commun 2011 32(11), 1046-51. Veliparib (ABT-888) purchased from Selleck.

    T47D breast cancer cells were pretreated with indicated concentrations of ABT-888

     

     

    Dr.Zhang of Tianjin Medical University. Veliparib (ABT-888) purchased from Selleck.

  • in vivo suppression of PAR formation by the PARP inhibitor ABT-888 upon induction of DNA damage

    Primary human lung fibroblast cells (MRC-5) were pre-treated with the indicated concentration of the PARP inhibitor ABT-888 for two hours. Oxidative DNA damage was induced by 500 µM H2O2 for 10 min and cellular PARP activity was measured by immuno-staining of poly(ADP)-ribose (PAR) (right panels). The in vivo effect of PARP inhibition was compared to cells without DNA damage induction and inhibitor (control) and H2O2-treated cells without inhibitor.
    Average nuclear PAR staining intensities of more than 50 cells were statistically analysed by Kruskal-Wallis and the post-hoc Dunn’s Multiple Comparison tests (left panel). Asterisks indicate highly significant (p<1%) differences to H2O2-treated cells without PARP inhibitor. Thick horizontal bars mark medians and error bars the interquartile range.
     
     

     

    David Schrmann from University of Base. Veliparib (ABT-888) purchased from Selleck.

    Caption:  451 Lu is a melanoma cell line with high PARP expression that is resistant to temozolomide.  Treatment with 25 µM ABT-888 greatly increased sensitivity to temozolomide compared to cells without ABT-888 treatment as measured by MTS assay.

     

     

    Dr. Steve Reuland from University of Colorado Denver. Veliparib (ABT-888) purchased from Selleck.

  • Effect of ABT-888 on the viability of endometrial cancer cell line Hec50 and Ishikawa and ovarian cancer cell line SKOV3,Caov3 and PA-1 was detected by WST-1 method after 3 days treatment.

     
     

     

    Dr. Xiangbing Meng of University of Iowa. Veliparib (ABT-888) purchased from Selleck.

Purity & Quality Control

Choose Selective PARP Inhibitors

Biological Activity

Description Veliparib (ABT-888) is a potent inhibitor of PARP1 and PARP2 with Ki of 5.2 nM and 2.9 nM in cell-free assays, respectively. It is inactive to SIRT2. Phase 3.
Features Increases the efficacy of common cancer therapies such as radiation and alkylating agents.
Targets
PARP2 [1]
(Cell-free assay)
PARP1 [1]
(Cell-free assay)
2.9 nM(Ki) 5.2 nM(Ki)
In vitro

ABT-888 is inactive to SIRT2 (>5 μM). [1] ABT-888 inhibits the PARP activity with EC50 of 2 nM in C41 cells. [2] ABT-888 could decrease the PAR levels in both irradiated and nonirradiated H460 cells. ABT-888 also reduces clonogenic survival and inhibits DNA repair by PARP-1 inhibition in H460 cells. ABT-888 increases apoptosis and autophagy in H460 cells when combination with radiation. [3] ABT-888 also inhibits PARP activity in H1299, DU145 and 22RV1 cells and the inhibition is independent of p53 function. ABT-888 (10 μM) suppresses the surviving fraction (SF) by 43% in the clonogenic H1299 cells. ABT-888 shows effective radiosensitivity in oxic H1299 cells. Furthermore, ABT-888 could attenuate the SF of hypoxic-irradiated cells including H1299, DU145 and 22RV1. [4]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
C41 NIL3fJBMcW6jc3WgRZN{[Xl? MYmzNEBucW5? NX;oNGIzUW6qaXLpeIlwdiCxZjDQRXJROSC5aYToJGVEPTBib3[gNE4xODJizszN MlPpNVk5QDh5NkC=
Jurkat M4LaTmtqdmG|ZTDBd5NigQ>? NHT6XYI6PiCq MlHISG1UVw>? MX3Jcohq[mm2aX;uJI9nKFCDUmCxJIF{e2W|c3XkJIF{KHKnZIXjeIlwdiCxZjDj[YxtKH[rYXLpcIl1gSC5aYToJGVEPTBib3[gN{DPxE1? MlrONlM5PTBzOUm=
Capan1 MlywS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEH4XGQ4OiCq M{TZU2ROW09? NF[0PWdCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JGJTS0F{IHflcoUhdXW2YYTl[EBpfW2jbjDDZZBidjFiY3XscJMhf2m2aDDJR|UxKG:oIEO5Mlch|ryP M4PWO|I1Ozl6M{iz
DT40 M{DROmN6fG:2b4jpZ{BCe3OjeR?= M1n4OlczKGh? MX\EUXNQ NUS5NIlpS3m2b4TvfIlkcXS7IHHnZYlve3RiY3jpZ4tmdiCEUlPBNk1l\W[rY3nlcpQhTFR2MDDj[Yxtew>? NILtdGMzPDl{MkW4Oy=>
ML-1 NWjFNll2SXCxcITveIlkKEG|c3H5 MUCyMlUh|ryP MnHWNlQhcA>? M4\I[2ROW09? MWnTfY5memerc4TpZ4FtdHliZX7oZY5k\XNiVGLBTWwucW6mdXPl[EBieG:ydH;zbZMhcW5iTVytNUBk\Wyucx?= M1vWNlI1QDl3MUO1
HCT-116 MnzQT4lv[XOnIFHzd4F6 NUT6OZVbOC53IN88US=> M{e2UFI1KGh? MYnQRXJRKGGldHn2bZR6KGSnY4LlZZNmew>? MYOyN|A2PDJzMx?=
UM-SCC1 M4\4TmN6fG:2b4jpZ{BCe3OjeR?= NVPHdI1QOTBizszN NVXiZVliOjRiaB?= MVXS[YR2[2W|IITo[UBk\WyuII\pZYJqdGm2eR?= NY\sXlBROjF7MUK2NlA>
FaDu NHvMeVNEgXSxdH;4bYMhSXO|YYm= MonjNVAh|ryP NHPmTFYzPCCq M2nINXJm\HWlZYOgeIhmKGOnbHygeoli[mmuaYT5 NF7mPHAzOTlzMk[yNC=>
PC-3 MkDmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MY[xNEDPxE1? MUnJcoR2[2W|IHGgd4lodmmoaXPhcpQhcW6qaXLpeIlwdiCrbjDjc4xwdnliZn;ycYF1cW:wwrC= NHnwc|QzOTV5MUmxNi=>
EoL-1-cell NFvnUolIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUnJR|UxRTFwMEe5PEDPxE1? MXPTRW5ITVJ?
NCI-SNU-5 MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mmr6TWM2OD1|LkGyPFQyKM7:TR?= Mny2V2FPT0WU
BV-173 M4HoT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NU\yOIJJUUN3ME21MlQ2PDB7IN88US=> NWm3U3hUW0GQR1XS
HCC1806 Mlv2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEPkbpRKSzVyPUWuO|UyPzNizszN NE\RfXVUSU6JRWK=
COLO-680 NFLyfG9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlPlTWM2OD14LkKxOFA3KM7:TR?= MXrTRW5ITVJ?
HCC2218 MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGfJbHRKSzVyPUeuO|k4ODRizszN NHXmNGtUSU6JRWK=
SK-MEL-24 MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXfJR|UxRTdwOEG5NlQh|ryP NGHDXo1USU6JRWK=
NCI-H720 Mof2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NF[5RYRKSzVyPUiuOFM3ODNizszN MXTTRW5ITVJ?
KASUMI-1 MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUjudIw2UUN3ME24Mlg6OjZ4IN88US=> NYG2cG01W0GQR1XS
HAL-01 M2L5eWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2XSdGlEPTB;OT64PFYzKM7:TR?= M4fuPHNCVkeHUh?=
CAL-33 MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmLPTWM2OD1zMD60N|Qh|ryP M3XpUXNCVkeHUh?=
SK-MEL-1 NXzsZ5JCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NF\KUHVKSzVyPUGyMlQ3PjNizszN MULTRW5ITVJ?
Ramos-2G6-4C10 Moq0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4XCeWlEPTB;MUKuOFc2OiEQvF2= MYfTRW5ITVJ?
KY821 MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGHVTmNKSzVyPUGyMlQ5PSEQvF2= Mlf2V2FPT0WU
HEC-1 MmDFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXzJR|UxRTF{LkmxPVYh|ryP NI\jd|FUSU6JRWK=
SK-NEP-1 MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4O0cmlEPTB;MUOuNVY3KM7:TR?= NFr6W2VUSU6JRWK=
MN-60 NEXLVVFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXL2PY1zUUN3ME2xN{42Ozh7IN88US=> NF6wfFRUSU6JRWK=
DU-145 MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NV[5dWtuUUN3ME2xN{46ODV|IN88US=> MVnTRW5ITVJ?
EW-3 NUHxcJlRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NH\LR2lKSzVyPUG0MlU2PjVizszN M3e3R3NCVkeHUh?=
OS-RC-2 M3rpN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHfYT3lKSzVyPUG1Mlk2QDlizszN NIfVVYhUSU6JRWK=
RPMI-8226 M3eyXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYTJR|UxRTF4LkKwOFIh|ryP M4HscnNCVkeHUh?=
ChaGo-K-1 Ml;ES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlnsTWM2OD1zNj61N|I2KM7:TR?= NVS0bpp3W0GQR1XS
DEL MkCzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml[4TWM2OD1zNj62O|E4KM7:TR?= NHr0bndUSU6JRWK=
GP5d MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3jhemlEPTB;MUeuNFU{KM7:TR?= NGmwb3FUSU6JRWK=
COLO-668 MmWxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUXJR|UxRTF5Lk[yPVQh|ryP M{jaS3NCVkeHUh?=
H9 MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUnYN442UUN3ME2xPE4zQDN|IN88US=> NI\wRpBUSU6JRWK=
NKM-1 M2ThbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFvPWm1KSzVyPUG4MlUyOTlizszN NHPGNnRUSU6JRWK=
KYSE-150 MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Ml3xTWM2OD1zOD65PVg3KM7:TR?= MlfqV2FPT0WU
Daoy MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NG[xOXZKSzVyPUG5MlU3PDlizszN NHLwXFBUSU6JRWK=
ECC10 MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MknjTWM2OD1{MD63OFU2KM7:TR?= NHLzRopUSU6JRWK=
A388 NX;Vepk4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXnzbGZoUUN3ME2yNU46ODlzIN88US=> NXP5S3VFW0GQR1XS
MHH-NB-11 NFHXZpRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1PvcGlEPTB;MkOuNVM3OyEQvF2= MmC3V2FPT0WU
HCC1937 M1nuTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnLKTWM2OD1{ND63OFYh|ryP MnX4V2FPT0WU
TGBC11TKB MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3XlVWlEPTB;MkWuOlg3OyEQvF2= MVfTRW5ITVJ?
CTV-1 Mlu5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2mwfWlEPTB;MkWuPFk3QSEQvF2= M3;PU3NCVkeHUh?=
NCI-H2029 MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoPQTWM2OD1{Nj60NlM5KM7:TR?= Mn;rV2FPT0WU
HLE NXHqOZBJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M333RWlEPTB;MkeuNFU1KM7:TR?= NFXaRpVUSU6JRWK=
NCI-H1693 MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoDlTWM2OD1{Nz6yPFk5KM7:TR?= M3H6XnNCVkeHUh?=
HCC70 MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUTYdYJ2UUN3ME2yO{44OjR4IN88US=> Mke5V2FPT0WU
BEN M{PtdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVP3WWN5UUN3ME2yO{46PTZ4IN88US=> NYP2UnR{W0GQR1XS
LB771 MmKzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV7SSm5DUUN3ME2yPE45Ozd|IN88US=> Mn\CV2FPT0WU
697 NYnXN3I1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmDkTWM2OD1{OT6wNlM2KM7:TR?= MVnTRW5ITVJ?
LU-139 MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnPaTWM2OD1{OT6zO|Q5KM7:TR?= NVrXboNnW0GQR1XS
EW-13 M4rJfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkDmTWM2OD1{OT6zPFE1KM7:TR?= MVLTRW5ITVJ?
MOLT-13 NH7yOpBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2nyUmlEPTB;MkmuN|gyPCEQvF2= NV3CW3ZLW0GQR1XS
L-363 M13XWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3PibmlEPTB;MkmuOFc6QCEQvF2= MXTTRW5ITVJ?
EM-2 MmHsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYHDU5JOUUN3ME2yPU41QTBzIN88US=> NYi2XYV5W0GQR1XS
RS4-11 M17TZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXLJR|UxRTNyLkSyOFEh|ryP NUG1[llJW0GQR1XS
A2780 M{DqTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NH;QfmtKSzVyPUOwMlc1PTdizszN M4XXNHNCVkeHUh?=
KU812 Ml\rS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NX;kbGFMUUN3ME2zNk4{PjR{IN88US=> M{\MdXNCVkeHUh?=
COLO-684 MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1HpeWlEPTB;M{OuN|U6QSEQvF2= MkDnV2FPT0WU
MFE-280 MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVjJR|UxRTN|LkO4PFkh|ryP NFTiO29USU6JRWK=
KG-1 MmDWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGG1c4dKSzVyPUOzMlYxODFizszN M1rm[3NCVkeHUh?=
JVM-3 MoS0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVrYNIdyUUN3ME2zOU42QDZ6IN88US=> NFPxb5RUSU6JRWK=
MV-4-11 M33hSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3T1fWlEPTB;M{WuPFQ6QSEQvF2= NWrQe3VIW0GQR1XS
LAMA-84 Ml3OS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXHi[2oxUUN3ME2zOk44OzR3IN88US=> M2TuXXNCVkeHUh?=
MOLT-16 NILQVIhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWDJR|UxRTN4Lkm1NkDPxE1? M2jHfHNCVkeHUh?=
H4 NFPyc4NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWfJR|UxRTN5LkW2O{DPxE1? NH7N[nNUSU6JRWK=
T47D MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlfhTWM2OD1|Nz63NFE5KM7:TR?= NWrzeFJQW0GQR1XS
CAL-54 NHz1TphIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmTkTWM2OD1|Nz65OlYh|ryP M3WyS3NCVkeHUh?=
SW982 MkXXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFHVS2dKSzVyPUO4MlA6QThizszN M3G5eHNCVkeHUh?=
IGROV-1 NIPEZm5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGW5eVRKSzVyPUO5MlM{ODRizszN MVfTRW5ITVJ?
NB14 NVzoPJhPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoD3TWM2OD12MD63NFMyKM7:TR?= NWjFbVJIW0GQR1XS
HCC1187 MmPhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEjFRYlKSzVyPUSxMlI4PzFizszN NH7rVlBUSU6JRWK=
SBC-1 NIT1NmFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHrDWZJKSzVyPUSxMlMxPjNizszN MXrTRW5ITVJ?
KARPAS-45 M3rYSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2PVUWlEPTB;NEGuOFgyQCEQvF2= MlLNV2FPT0WU
MOLT-4 MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXPJR|UxRTR{LkK1N|gh|ryP MWjTRW5ITVJ?
JVM-2 NEjRdXZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MX7JR|UxRTR{LkmyNFch|ryP NIWwO4pUSU6JRWK=
A4-Fuk M2HZSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFrTWGpKSzVyPUSzMlU3QTFizszN MU\TRW5ITVJ?
MDA-MB-361 NHvSOlhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2K4RmlEPTB;NEOuPFQyPCEQvF2= MVPTRW5ITVJ?
BALL-1 NXLSZXFtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXnNT|MzUUN3ME20N{46PTN{IN88US=> MWPTRW5ITVJ?
T98G M4XSXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYXDfXhXUUN3ME20OE45PTF5IN88US=> NWWwVoVpW0GQR1XS
Mo-T MmfSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnPpTWM2OD12NT62N|g6KM7:TR?= NYDLRnluW0GQR1XS
MHH-PREB-1 NITp[oFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3fqc2lEPTB;NEWuO|U5PSEQvF2= NVvxToNsW0GQR1XS
ALL-PO NV7lUHJGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWXJR|UxRTR5LkO3PVEh|ryP M3vQXXNCVkeHUh?=
NCI-H510A NV3wdmk3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUPJR|UxRTR5LkmwN|Qh|ryP M3\jdXNCVkeHUh?=
ML-2 M{T3SGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnPZTWM2OD12OT63PFU3KM7:TR?= NFLNTFNUSU6JRWK=

... Click to View More Cell Line Experimental Data

In vivo The oral bioavailability of ABT-888 is 56%-92% in mice, Sprague-Dawley rats, beagle dogs, and cynomolgus monkeys after oral administration. [1] ABT-888 (25 mg/kg i.p.) could improve tumor growth delay in a NCI-H460 xenograft model with well tolerated. Combination with radiation, ABT-888 decreases the tumor vessel formation. [3] ABT-888 reduces intratumor PAR levels by more than 95% at a dose of 3 and 12.5 mg/kg in A375 and Colo829 xenograft models and the suppression could be maintained over time. [4]

Protocol

Animal Research:

[1]

+ Expand
  • Animal Models: NCI-H460, H460, B16F10 and 9L xenografts in C57BL/6 mice
  • Formulation: Formulated in solution containing 0.9% NaCl adjusted to pH 4.0
  • Dosages: ~25 mg/kg
  • Administration: Orally administered
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 17 mg/mL (69.58 mM)
Water Insoluble
Ethanol Insoluble
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
0.5% methylcellulose+0.2% Tween 80
For best results, use promptly after mixing.
5 mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 244.29
Formula

C13H16N4O

CAS No. 912444-00-9
Storage powder
in solvent
Synonyms NSC 737664

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT01540565 Completed BRCA1 Mutation Carrier|BRCA2 Mutation Carrier|Ovarian Epithelial Tumor|Recurrent Fallopian Tube Carcinoma|Recurrent Ovarian Carcinoma|Recurrent Primary Peritoneal Carcinoma National Cancer Institute (NCI) April 9 2012 Phase 2
NCT00553189 Completed Solid Tumors|Lymphomas National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) August 9 2007 Phase 1
NCT03289910 Suspended Acute Myeloid Leukemia|Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome|Atypical Chronic Myeloid Leukemia BCR-ABL1 Negative|Chronic Myelomonocytic Leukemia|Essential Thrombocythemia|Myelodysplastic/Myeloproliferative Neoplasm|Myelofibrosis|Polycythemia Vera|Recurrent Adult Acute Myeloid Leukemia|Refractory Acute Myeloid Leukemia National Cancer Institute (NCI) June 8 2018 Phase 2
NCT02595905 Recruiting Breast Carcinoma Metastatic in the Brain|Deleterious BRCA1 Gene Mutation|Deleterious BRCA2 Gene Mutation|Estrogen Receptor Negative|HER2/Neu Negative|Progesterone Receptor Negative|Recurrent Breast Carcinoma|Stage IV Breast Cancer AJCC v6 and v7|Triple-Negative Breast Carcinoma National Cancer Institute (NCI) July 7 2016 Phase 2
NCT01749397 Active not recruiting Stage IV Fallopian Tube Cancer AJCC v6 and v7|Stage IV Ovarian Cancer AJCC v6 and v7|Stage IV Primary Peritoneal Cancer AJCC v7 National Cancer Institute (NCI) December 7 2012 Phase 1
NCT02163694 Active not recruiting Metastatic Breast Cancer AbbVie August 5 2014 Phase 3

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

PARP Signaling Pathway Map

PARP Inhibitors with Unique Features

Related PARP Products

Tags: buy Veliparib (ABT-888) | Veliparib (ABT-888) supplier | purchase Veliparib (ABT-888) | Veliparib (ABT-888) cost | Veliparib (ABT-888) manufacturer | order Veliparib (ABT-888) | Veliparib (ABT-888) distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID